REMEDi4ALL, an ambitious EU-funded research initiative, launches to drive forward the repurposing of medicines in Europe
To advance knowledge in this field and address substantial obstacles -fragmented and siloed research; non-standardised datasets; heterogenous quality of computational tools; poor patient engagement or lack of incentives and policies to support and enhance drug repurposing- the European Union (EU) through the Horizon Europe (HE) programme will invest 23 million euros in REMEDi4ALL over the next 5 years. It is expected that, due to REMEDi4ALL, more (and better) repurposed therapeutics will be widely available thanks to more agile, cutting-edge development processes, ultimately contributing to increased sustainability of health systems.
A favourable eco-system for drug repurposing
The project kicks off with the ambition of establishing a European research and innovation eco-system that facilitates fast and cost-effective patient-centric development and access to repurposed medicines. To this end, REMEDi4ALL will:
- build a state-of-the-art platform to provide expertise and services across the complete value chain (scientific, methodological, financial, legal, regulatory, intellectual property) for patient-centric medicine repurposing at every development stage and in any disease area.
- assemble advanced in silico tools for Machine Learning (ML) and Artificial Intelligence (AI), open datasets and tools and expertise required to understand the mechanism of action of specific medicines.
- create a global community of practice connected in a think-tank-like environment through impactful multidisciplinary activities and events.
- train and educate the next generation of researchers, clinicians, patients, policymakers, regulators and funders in cutting-edge drug repurposing tools and processes.
- favour dialogue and debate to advance policy and fair access to repurposed medicines across the EU.
REMEDi4ALL has selected four medicine repurposing projects in different stages of development to demonstrate the viability of the newly created platform. Each project covers a different therapeutic area with high unmet medical needs– pancreatic cancer, COVID-19, rare diseases and ultra-rare diseases. These projects will first be onboarded to ensure a patient-centric approach before testing all elements of the platform to optimise its tools and services.
A multidisciplinary effort to cover every aspect of drug repurposing
The REMEDi4ALL consortium brings together a unique combination of expertise to address the complexities of drug repurposing. Under the leadership of EATRIS, the European infrastructure for translational medicine, 24 organisations in the fields of clinical and translational research, clinical operations, patient engagement and education, regulatory framework, funding, governance, Health Technology Assessment (HTA) or pricing and reimbursement will closely collaborate to make drug repurposing mainstream.
Anton Ussi, CEO at EATRIS ERIC:
‘It’s an enormous privilege to work with this team of leading international experts, institutions and patient representatives in such an important and high potential area for European health. REMEDI4ALL will truly transform drug repurposing by making the process more transparent, efficient and – most importantly – completely patient-centred.’
The 24 partners participants include:
- EATRIS (Coordinator) – The Netherlands
- Fraunhofer-Gesellschaft – Germany
- Helsingin yliopisto (FIMM-UH) - Finland
- European Clinical Research Infrastructure Network (ECRIN) - France
- Istituto Di Ricerche Farmacologiche Mario Negri (IRFMN) - Italy
- Istituto Nazionale Tumori Fondazione Pascale (INT-NA) - Italy
- European Organisation For Rare Diseases (EURORDIS) – France
- Dompé farmaceutici Spa (DOMPÉ) – Italy
- ZonMw - The Netherlands
- Teamit Research - Spain
- Medicines For Europe (M4EU) - Belgium
- Syreon Kutato Intezet Korlatolt Felelossegu Tarsasag (SRI) - Hungary
- Karolinska Institutet (KI) - Sweden
- Chemotargets - Spain
- Anticancer Fund (ACF) - Belgium
- Univerza V Ljubljani - Slovenia
- Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) - Germany,
- Istituto Ortopedico Rizzoli (IOR) - Italy
- Servicio Madrileño De Salud (SERMAS) - Spain
- Uppsala Universitet (UU) - Sweden
- Universitaetsmedizin Goettingen (UMG) – Germany
- Beacon: For Rare Diseases (BEACON) - United Kingdom The University Of Sheffield (USFD) - United Kingdom
- University Of Hull (UHULL) – United Kingdom
ZonMw -The Netherlands
In REMEDi4ALL, ZonMw has the lead in creating a funders network and ‘think tank’ with the aim to discuss policy issues, share best funding practices, co-ordinate (new) funding streams, promote joint calls and develop innovative co-funding models for drug repurposing. ZonMw will also contribute to improving the market access and policy environment for drug repurposing.
Heleen van der Meer, senior programmamanager International Drug Repurposing / WP9 leader REMEDi4ALL
Dunja Huijbers, senior programmamanager Drug Rediscovery / Goed Gebruik Geneesmiddelen